Review Article

Pharmaceutical BIOPROCESSING

Pharmaceutical Bioprocessing: Different Microbial Pectin and Pectinase

Abstract

The use of microbial pectinase in several sectors has boosted the demand for it globally. Bacteria, fungus, and yeast are the principal sources of pectinase in food. In order to produce pectinase, low-cost agro-industrial waste has been preferred as a substrate. Temperature, pH, and production timeframes, which are the primary determinants in pectinase synthesis, were among the parameters that could not be optimised for pectinase production. Due to its many benefits, the pectinase enzyme is receiving attention; however, further research is required to fully utilise this enzyme in a variety of sectors. The structure of pectin, the substrate for pectinase synthesis, variables that affect pectinase production, the industrial use of microbial pectinase.

Keywords: Biochemical properties • Depolymerisation • Pectinase • Pharmaceutical application • Production method

Caroline Roy*

Department of Chemical Engineering, Virginia

*Author for correspondence:

roycaroline@rediff.com

Received: 02-Mar-2023, Manuscript No. FMBP-23-92384; **Editor assigned:** 04-Mar-2023, PreQC No. FMBP-23-92384 (PQ); **Reviewed:** 18-Mar-2023, QC No FMBP-23-92384; **Revised:** 23-Mar-2023, Manuscript No. FMBP-23-92384 (R); **Published:** 30-Mar-2023, DOI: 10.37532/2048-9145.2023.11(2).22-25

Introduction

Pectin and pectinase are essential macromolecules in the field of biotechnology. These molecules are a practical, non-toxic invention of nature with broad applicability. Understanding pectic compounds, their structure, special depolymerisation, biological characteristics like a catalytic mechanism, and the strong interaction among these molecules might greatly increase their applicability in industries. For instance, learning more about the diverse molecular heterogeneity of the compounds might be the main focus for resolving industrial problems on a number of fronts. In the current review, an effort has been made to organise the basic knowledge on the kinds and biochemical properties of pectinase as well as the structure, de-polymerization traits, and classification of pectin. This page also discusses numerous production techniques related to the product's substantial contribution to the pharmaceutical business (whether it be pectinase or derived pectic compounds).

Over the past 20 years, the pharmaceutical industry has drastically changed, shifting from broadly acting drugs to extremely specialised biomedicines. Additional medication categories have appeared, and sophisticated genetic sequence identification diagnostics are now commonplace. Better illness management and perhaps even treatments for fatal diseases are promised by the bioprocessing revolution. Due to the need for new manufacturing techniques for these innovative medicinal procedures, it also presents manufacturing hurdles. The impact is particularly significant for purification trains, where process designers must deal with combinations that are difficult to filter and are becoming more complicated. To address these issues, makers of drugs and diagnostics need reliable purifying solutions and technical assistance [1-5].

In a commercial bioreactor for the production of biopharmaceuticals, bioprocessing is the process of increasing the quantity of living cells or other biologic systems/components (such as bacteria, viruses, enzymes, proteins, or nucleic acids). The majority of the high-value medications and vaccines produced by the bioprocessing industry are essential for the development of contemporary healthcare. It is crucial that the processing system is free of any pollutants, especially microbiological contamination, as bioprocessing depends on the growth and harvesting of priceless biological cells/systems.

Discussion

Any pharmaceutical medicine made from, extracted from, or partially synthesised from biological

sources is referred to as a biopharmaceutical, sometimes known as a biological medicinal product or biologic. These include vaccinations, whole blood, blood components, allergenic, somatic cells, gene treatments, tissues, recombinant therapeutic protein, and living drugs used in cell therapy, which are distinct from pharmaceuticals that are entirely produced. In addition to being made up of living cells or tissues, biologics can also be made up of complicated combinations of nucleic acids, proteins, and carbohydrates. They are isolated from live sources, such as human, animal, plant, fungus, or microorganisms, or their antecedents or constituent parts. They are applicable to both human and veterinary medicine.

A wide range of equipment for specialised uses and applications is included in bioprocessing equipment. Equipment can be broadly categorised into three groups based on how it affects a process: upstream, downstream, and support. Upstream machinery deals with the development of a host organism to create a finished good. The end result could be the organisms themselves, something they hold inside of them, or something they defecate into the growing media. The downstream machinery purifies the harvest that results from the upstream operation, for instance, through filtration and chromatography. Support equipment includes other items used in biomanufacturing include incubators, utility carts, liquid mixers, holding tanks, bead mills, and various cell disruptors. There is a great deal of research and interest in process analytical technology (PAT), the regulatory drive for integrating quality in pharmaceutical manufacturing. If PAT is successfully implemented in bioprocesses, this can improve process comprehension and control, reduce the danger from inferior drug products to both the manufacturer and the patient, and increase process control. The entire PAT framework must be taken into account in order to maximise the benefits of PAT and each component of PAT, such as sensor and analytical technology, data analysis methods, control strategies and algorithms, and process optimization procedures, must be properly chosen. The current state of PAT in the biopharmaceutical business is covered in this chapter, along with multiple case studies illustrating the level of maturity of various PAT tools. QbD component's Graphical Abstract Hierarchy [6-10].

The use of enzymes in numerous industrial industries has significantly increased over the ages. This is due to the possibility that some hazardous chemicals that were formerly employed in the processing of food could be replaced by enzymes. The researchers have a significant difficulty with biotechnological approaches that involve identifying microbial enzymes, determining their mechanisms of action, and scaling up production. Recombinant enzymes can be engineered to work more quickly in a variety of ways by using protein engineering in addition to recombinant techniques. Due to their extremely significant action and practicality, numerous microbe-borne enzymes (such as amylase, cellulase, glucosidases, invertases, keratinases, lactase, ligninase, lipase, penicillinase, protease, and xylanase) have been produced and commercially successful.

Pectinase, an enzyme, has sparked attention across the globe as a biological catalyst in numerous industrial processes. This enzyme disintegrates the pectin that is typically present in plant cell walls, and it is therefore well-known for the commercial preparation of clear fruit juice, the liquefaction and saccharification of plant biomass, the production of paper, as well as the fermentation of coffee and tea. Galacturonic acid is abundant in pectin, an acidic hetero-polysaccharide with carboxyl groups that have been esterified with methanol. Cereals, vegetables, and fruits contain a large amount of the acidic hetero-polysaccharide.

Conclusion

As almost every industrial sector—including food, feed, and pharmaceuticals—is significantly impacted by enzymes, the market for industrial enzymes is rising quickly to keep up with consumer demand. Enzymes' stability and expense, however, prevent them from being used as quickly as they might in industrial domains. The stability of the enzyme under harsh temperature, acidic pH conditions, and organic solvents is crucial for commercialization. Enzymes' weak resilience to harsh industrial environments restricts their use in industrial processes. To maximise pectinase synthesis, a variety of methods can be utilised; however, because enzymes are unstable, the price of widespread application is greater. Researchers are paying more attention to thermophilic enzymes since it is difficult and expensive to regulate temperature during large-scale fermentation operations. One of the most crucial considerations is the economic viability of generating pectinase from certain microorganisms and establishing environmental

parameters. To increase the number and quality of finished goods, pectinases can be utilised in a range of industrial processes. In this method, it's crucial to consider the physicochemical makeup and manufacturing procedure of new enzymes. Research should be done on the immobilisation of the pectinase enzyme for reuse in order to further lower the total cost. Because the alterations are totally under control, genetic engineering is a much more effective solution. The appropriate gene from the microorganism that naturally generates a certain enzyme (donor) is taken in this method and inserted into a different microbe that will manufacture the enzyme more effectively (host). Finding strains that generate pectinase in conjunction with other enzymes requires more research, and the precise combination is required for each application. This will considerably lower the cost of production for a particular application. Future research on pectinolytic enzymes should concentrate on determining the molecular processes that control enzyme secretion as well as the modes of action of diverse pectinolytic enzymes against various agro-industrial pectic substrates. In this manner, well-designed research can offer crucial tools for controlling microorganisms to create large amounts of effective and affordable enzymes. New enzyme-based technologies that are more ecologically friendly have been developed by the textile industry thanks to advancements in enzymology, molecular biology, and screening methods. All operations in the future seem to be capable of being completed by pectinases. Industrial uses of pectinases include the production of textiles, the processing of fruits, the extraction of oils, and the fermentation of coffee and tea. The involvement of pectinases in numerous industrial processes has been found to be oddly recognised, with hopeful results, it is concluded. It is abundantly obvious from the research that pectinolytic enzymes have been prioritised for major development or upgrading of enzymes for industrial purposes. Research should thus concentrate on protein engineering to produce more reliable and adaptable pectic enzymes as well as the optimization of production methods utilising novel strains in order to ensure the success of this method for the use of microbial pectinase.

In the current period of breakthroughs and cutting-edge study for discovering the innovative value of microorganisms and their products, there has been an unstoppable rebirth brought about by microbial research. The involvement of pectinases and/or pectins is found to be oddly recognised in a variety of industrial processes, with encouraging outcomes, it is concluded. It is evident from the substantial research that pectinolytic enzymes have taken on a crucial role in the development or upgrading of enzymes important to industrial products. The cost-effectiveness of producing these enzymes from chosen microorganisms and applied environmental conditions is one of the most important variables, though. As can be seen, the use of pectinase and other derived pectic compounds in pharmaceutical goods has received the least attention. Thus, there is a pressing need to increase and broaden the use of these beneficial enzymes in the pharmaceutical business. Moreover, biotechnological elements must play a significant role in the creation of a broad-spectrum pectinase with high catalytic affinities. Hence, detailed understanding of the expression mechanism at the molecular and biochemical levels is crucial.

References

1. Berthe-Aucejo A, Nguyen PKH, Angoulvant F *et al*. Retrospective study of irrational prescribing in French paediatric hospital: Prevalence of inappropriate prescription detected by Pediatrics: Omission of Prescription and Inappropriate prescription (POPI) in the emergency unit and in the ambulatory setting. *BMJ Open***.** 9, 45-66(2015).
2. Al Balushi KA, Al-Sawafi F, Al-Ghafri F *et al*. Drug utilization pattern in an Omani pediatric population. *J. Basic Clin Pharm.* 4, 68–72(2014).
3. Al-Badri A. Almuqbali J, Al-Rahbi K *et al*. A Study of the Paediatric Prescriptions at the Tertiary Care Hospital in Oman. *J Pharmaceut Res.* 5, 17-56(2020)
4. Al-Maqbali, Haridass S, Hassali M *et al*. Analysis of Pediatric Outpatient Prescriptions in a Polyclinic of Oman. Glob. *J Med Res.* 19, 2249–4618(2019).
5. Bakaki PM, Horace A, Dawson N *et al*. Defining pediatric polypharmacy: A scoping review. *PLoS ONE* , 13, 56-99(2018).
6. Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. *Am J Epidemiol.* 115, 92–106(1982).
7. Wallace E, McDowell R, Bennett K *et al.* Impact of Potentially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study. *J Gerontol A Biol Sci Med Sci.* 72,

271–277(2017)

8. Cahir C, Moriarty F, Teljeur C *et al*. Potentially inappropriate prescribing and vulnerability and hospitalization in older community-dwelling patients. *Ann Pharmacother.* 48, 1546–1554(2018).
9. Cullinan S, O'Mahony D, Fleming A *et al*. A meta-synthesis of potentially inappropriate prescribing in older patients. *Drugs Aging*. 31, 631–638(2014).
10. Liew TM, Lee CS, Goh Shawn KL *et al*. Potentially Inappropriate Prescribing Among Older Persons: A Meta-Analysis of Observational Studies. *Ann Fam Med.* 17, 257–266(2019).